P/B
1,9
Immatics
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
$869.3M
Market Cap • 11/6/2026
2020
(6 years)
Founded
2020
(6 years ago)
IPO
NASDAQ
Listing Exchange
Germany
Country
Valuation
P/S
17,9
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
3,3
EPS
—
Market Cap
Market Cap
869,3M
EV
437,1M
EV/Revenue
9
EV/EBITDA
-1,8
EV/EBIT
-1,7
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-17,4%
Total Yield
-17,4%
Payout
0%
Retained Earnings
-1B
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
522,2%
Capex/Revenue
8,8%
Capex/D&A
30,6%
Capex/OCF
-1,8%
SBC/OCF
—
% PPE
10,6%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
5,8%
CAGR Op. Income 5Y
20,3%
CAGR Net Income 5Y
22,3%
CAGR EPS 5Y
-14,6%
CAGR OCF 5Y
15,3%
Leverage
N.D./EBITDA
1,7
Debt/Equity
0%
Current Ratio
7,5
Quick Ratio
7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!